Participating Companies

4D Molecular Therapeutics
Fo­cused on the dis­cov­ery and de­vel­op­ment of pro­pri­e­tary tar­get­ed AAV gene ther­a­py vec­tors and ther­a­peu­tic prod­ucts through a ro­bust dis­cov­ery plat­form, termed Ther­a­peu­tic Vec­tor Evo­lu­tion. Th­ese... [more in­for­ma­tion]
Aurinia Pharmaceuticals, Inc. [AUPH] US$591 MM MCap
De­vel­op­ing vo­clos­porin ad­dress­ing lu­pus nephri­tis (LN), fo­cal seg­men­tal glomeru­los­cle­ro­sis (FS­GS) & dry eye syn­drome (DES). - Dry eye top-line da­ta: ear­ly Q1 19 - LN top line da­ta: late Q4 19 - FS­GS... [more in­for­ma­tion]
CytomX Therapeutics, Inc. [CTMX] US$470 MM MCap
Anti­body pro­drug (Pro­body) plat­form. Pro­body ther­a­peu­tics with pro­tease-cleav­able masks are de­signed to se­lec­tive­ly bind within the tu­mor mi­croen­vi­ron­ment. Cy­tomX is cur­rent­ly de­vel­op­ing part­nered and... [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Fo­cused on treat­ments for fi­brot­ic dis­eas­es by har­ness­ing the ther­a­peu­tic po­ten­tial of in­te­grin bi­ol­o­gy and TGF-&be­ta; mo­d­u­la­tion. Lead pro­gram is a small molecule du­al se­lec­tive in­hibi­tor of avb6/avb1... [more in­for­ma­tion]
Targovax [TRVX:OS] NKr540 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pa­tients w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2018 and 2019. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
Vericel Corporation [VCEL] US$796 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Epi­cel mar­ket: $2b+. Re­cord 3Q18 rev­enues of $22.5 M rep­re­sents 58% YOY in­crease. FY gui­dance... [more in­for­ma­tion]